Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,331 matching trials from the live ClinicalTrials.gov search.
Conditions
Hematologic Malignancies
Interventions
Clofarabine, Stem Cell Transplantation, Hematopoietic, OKT3, Thiotepa, Melphalan, Mycophenolate mofetil, Rituximab, G-CSF
Drug · Procedure · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia
Interventions
G-CSF mobilized CD34+ selected cells for transplantation
Biological
Lead sponsor
Emory University
Other
Eligibility
17 Years to 75 Years
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Hematologic Neoplasms, Multiple Myeloma, Anemia, Aplastic, Hemoglobinuria, Paroxysmal, Myelofibrosis
Interventions
busulfan, and melphalan, and alemtuzumab
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Lymphoma
Interventions
Vorinostat, Gemcitabine, Busulfan, Melphalan, Stem Cell Infusion, Rituximab, G-CSF, Palifermin, Dexamethasone acetate
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Conditions
Leukemia
Interventions
Busulfan, Fludarabine, Clofarabine, Total Body Irradiation (TBI), Thymoglobulin, Stem Cell Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Decitabine, Cytarabine, Idarubicin
Drug · Radiation · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hematologic Malignancies, Nonmalignant Diseases, Immunodeficiencies, Hemoglobinopathies, Genetic Inborn Errors of Metabolism, Fanconi's Anemia, Thalassemia, Sickle Cell Disease
Interventions
Melphalan
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
San Francisco, California
Conditions
Allogeneic Stem Cell Transplant, Leukemia, Non-Hodgkins, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 55 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New York, New York
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Leukemia, Lymphoma, Oral Complications
Interventions
filgrastim, palifermin, cyclophosphamide, etoposide, ifosfamide, peripheral blood stem cell transplantation, quality-of-life assessment, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Accepts healthy volunteers

Virtual Reality Experiences for Anxiety and Pain Control

NCT04759183
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Survey Administration, Virtual Reality Game, Virtual Reality Meditation
Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 89 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Cognitive/Functional Effects, Depression, Hematopoietic/Lymphoid Cancer, Malnutrition, Pain, Psychosocial Effects of Cancer and Its Treatment, Unspecified Adult Solid Tumor, Protocol Specific, Weight Changes
Interventions
medical chart review, questionnaire administration, cognitive assessment, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
65 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Cleveland, Ohio
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Comprehensive Geriatric Assessment
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
65 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Mixed Phenotype Acute Leukemia
Interventions
Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Pretargeted Radioimmunotherapy, Total-Body Irradiation, Biospecimen Collection, Single Photon Emission Computed Tomography
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Terminated Phase 1Phase 2 Interventional Results available

BMS-986253 in Myelodysplastic Syndromes

NCT05148234
Conditions
Myelodysplastic Syndromes
Interventions
Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine, Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine, BMS-986253, Bone Marrow Biopsy, Bone Marrow Aspiration, ECG
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Electroencephalography, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, filgrastim, cyclophosphamide, fludarabine phosphate, thiotepa, allogeneic bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Hematologic Malignancies, Other Diagnoses, Comorbidities, and Complications
Interventions
Not listed
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
19 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Conditions
B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Graft Versus Host Disease, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
Interventions
thiotepa, cyclophosphamide, tacrolimus, methotrexate, sirolimus, total body irradiation
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
44
States / cities
Phoenix, Arizona • Duarte, California • Oakland, California + 40 more
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Bone Marrow Transplantation Recipient, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic Cell Transplantation Recipient, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Interventions
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine, Laboratory Biomarker Analysis, Placebo
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Duarte, California • Atlanta, Georgia • Boston, Massachusetts
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
alemtuzumab, cyclosporine, fludarabine phosphate, melphalan, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
24
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 19 more
Conditions
Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Graft Versus Host Disease, Hodgkin Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Secondary Myelodysplastic Syndrome
Interventions
Busulfan, Cyclophosphamide, Fludarabine Phosphate, Hematopoietic Cell Transplantation, Laboratory Biomarker Analysis, Melphalan Hydrochloride, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Quality-of-Life Assessment, Tacrolimus, Total-Body Irradiation
Drug · Procedure · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
5 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Duarte, California
Conditions
Adenovirus Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections, Stem Cell Transplant
Interventions
Multi-virus Specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Houston, Texas
Conditions
Multiple Myeloma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
Interventions
Plerixafor, Gcsf
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Thymic Carcinoma
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, melphalan, methylprednisolone, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
15
States / cities
Gainesville, Florida • Jacksonville, Florida • Tampa, Florida + 11 more